\
Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancerNew Podcast

Turning the Tide on Cancer

Investing in Cardiff Oncology to Provide New Treatment Options for Cancers with the Greatest Medical Need

Board of Directors

The following members make up Trovagene's Board of Directors.  Please select an individual member below to learn more about them and the committees they contribute to.

Dr. Adams has served as Executive Chairman since May 2020 and formerly as Chairman of the Board since April 2009 and as Chief Executive Officer from June 2018 to May 2020. He is currently a...

Lale White has been a director since 2020. She is the chief executive officer of XIFIN, Inc. (“XIFIN”), a health information technology company that leverages diagnostic information to improve...

Rodney Markin, MD, has been a Director since February 2014. He is currently Vice President for Network Development, Nebraska Medicine and Associate Vice Chancellor for Business and Executive...

Gary Jacob has been a Director since February 2009. He is Chief Executive Officer of Immuron Limited, an Australian public biotechnology company, where he has served since November 2018 and has...

James Armitage, MD, has been a director since 2020. Since 2003, he has been a professor of internal medicine in the division of hematology and oncology at the University of Nebraska Medical...

Gary Pace has been a director since 2020. He has been a director of Pacira Biosciences, Inc. since 2008, Simavita Ltd. since 2016 and Antisense Therapeutics since 2015 as well as a director of...

John Brancaccio, a retired CPA, has served as a director of Trovagene since December 2005. Since April 2004, Mr. Brancaccio has been the Chief Financial Officer of Accelerated Technologies, Inc.,...